MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Haven Appeal

McKesson's analyst price target has been trimmed to $941 from $950, reflecting analysts' slightly more conservative assumptions around policy, biosimilar, and GLP-1 uncertainties, while still incorporating potential long-term benefits from areas such as biosimilar co-manufacturing.

Analyst Commentary

Recent Street research on McKesson points to a mixed but engaged view of the stock, with several firms revising price targets and reassessing assumptions around policy risk, biosimilars, and GLP 1 exposure. For you as an investor, the key themes are how these factors may affect McKesson's execution, growth opportunities, and valuation over time.

Bullish Takeaways

Bullish analysts continue to reference confidence in McKesson's longer term business model, even when trimming targets, suggesting they still see room for execution on existing initiatives.
Comments from McKesson at a recent healthcare conference about potential biosimilar co manufacturing are being viewed as a source of optionality, with some analysts factoring this into their valuation work as a possible incremental growth driver.
Positive initiations and target increases from certain firms, including one suggesting a generally favorable view at initiation, indicate that some on the Street still see the risk or reward profile as attractive relative to current pricing.
Bullish analysts appear willing to look through near term uncertainty around policy and GLP 1 trends, focusing instead on McKesson's capacity to execute within its existing distribution and services platform.

Bearish Takeaways

Several bearish analysts have reduced McKesson price targets, signaling greater caution on valuation as they incorporate updated assumptions around the Inflation Reduction Act, biosimilars, and GLP 1 related pressures.
The repeated emphasis on "incrementally conservative" estimates suggests growing concern around visibility into key regulatory and product related variables, which may limit conviction in near term earnings trajectories.
Some firms have lowered McKesson's target enough to imply less upside from current levels, reflecting worries that policy risk and customer behavior in biosimilars could weigh on future fundamentals.
The addition of McKesson to a "Tactical Underperform" list by one research house highlights short term execution risk in the stock, even if longer term structural views are not uniformly negative.

What’s in the News for McKesson

McKesson selected Moore, Oklahoma for a new 330,000 square foot regional pharmaceutical distribution center. The facility is expected to replace an existing site, expand capacity, increase automation, and support pharmacies, hospitals, and healthcare providers across Oklahoma, Texas, and nearby states. (Source: McKesson distribution center announcement)
McKesson amended its credit agreement to add a US$2.25b senior secured term B loan maturing in 2032. The loan is secured by substantially all tangible and intangible assets of McKesson and certain U.S. subsidiaries, offers a floating rate option based on Adjusted Term SOFR plus a margin, and is aimed at increasing liquidity and financial flexibility. (Source: McKesson term loan filing)
Analysts continue to assign McKesson Strong Buy and Overweight ratings, even as several firms cut price targets. Explanations cited include sector wide multiple compression and regulatory questions, while highlighting the company’s operations in pharmaceutical distribution, oncology, prescription technology, and medical surgical solutions. (Source: analyst ratings roundup)
Apollo managed funds acquired about a 13% minority stake in McKesson’s Medical Surgical Solutions business, implying a valuation of roughly US$13b for that segment. McKesson retains majority control of the unit. (Source: Apollo investment announcement)
McKesson reported Q4 adjusted EPS of US$11.69, above Wall Street expectations, while revenue of US$96.3b came in below consensus. All 17 covering analysts maintained a consensus Strong Buy rating following the release. (Source: Q4 earnings recap)

Valuation Changes for McKesson

Fair Value: trimmed slightly from $949.73 to $941.40, a reduction of about 0.9%.
Discount Rate: effectively unchanged at 7.11%, indicating no material shift in the risk assumption being used.
Revenue Growth: kept broadly stable at about 7.37%, with only a very small numerical adjustment.
Net Profit Margin: held essentially flat at about 1.21%, with only a minor rounding change in the model.
Future P/E: reduced modestly from 20.83x to 20.65x, reflecting a slightly lower valuation multiple applied to McKesson's projected earnings.

1 view

Key Takeaways

Expansion into specialty pharmaceuticals and value-added services strengthens revenue quality, customer relationships, and recurring income streams.
Operational efficiency gains driven by automation and digitization support margin improvement and reinforce market leadership.
Regulatory pressures, industry consolidation, lower-margin generics, shifting healthcare access, and technology disruption all threaten McKesson's traditional revenue streams and long-term profit sustainability.

Catalysts

About McKesson

Provides healthcare services in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Growing demand for pharmaceuticals and medical supplies, fueled by an aging population and higher chronic disease rates, underpins accelerating prescription volume growth, which supports sustained top-line revenue expansion for McKesson.
Increasing adoption of specialty and oncology pharmaceuticals, alongside recent acquisitions (Core Ventures and PRISM Vision) that expand the provider network and service portfolio, are improving revenue mix quality and positioning the company for higher operating margins and earnings growth.
Investments in digitization, automation, and advanced analytics across distribution centers and logistics (e.g., automated picking systems, AI, robotics) are enhancing operational efficiency, driving measurable reductions in operating expenses and supporting long-term net margin improvement.
Expanding value-added services, such as pharmacy management, patient access/adherence solutions, and commercialization support for biopharma customers, allow for stronger customer relationships, greater recurring revenue streams, and improved revenue visibility.
Increasing complexity of the pharmaceutical supply chain (e.g., biosimilars, cold chain logistics, personalized medicine) disproportionately benefits large, sophisticated distributors like McKesson, enabling competitive market share gains and enhanced supply chain resiliency, contributing to both top-line and margin expansion.

McKesson Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming McKesson's revenue will grow by 7.4% annually over the next 3 years.
Analysts are assuming McKesson's profit margins will remain the same at 1.2% over the next 3 years.
Analysts expect earnings to reach $6.1 billion (and earnings per share of $55.08) by about June 2029, up from $4.8 billion today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 20.7x on those 2029 earnings, up from 18.8x today. This future PE is lower than the current PE for the US Healthcare industry at 23.6x.
Analysts expect the number of shares outstanding to decline by 3.36% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Rising regulatory and governmental pressure on drug pricing and healthcare costs could compress McKesson's profit margins over the long term, as the company notes the dynamic and policy-driven environment and ongoing engagement with policymakers-potentially threatening both revenue growth and net margins.
Accelerating vertical integration and consolidation among drug manufacturers, payers, and pharmacy benefit managers (e.g., PBMs adopting in-sourcing strategies, "Caremark in-sourcing") may disintermediate traditional wholesalers, reducing McKesson's addressable market and putting sustained pressure on long-term revenues and operating profits.
Steady transition toward biosimilars and generics, which are highlighted as only "steady contributors" to earnings and usually deliver lower gross margins than branded drugs, may limit future profit opportunities and drag on overall net margin expansion over time.
Potential declines in healthcare access and rising uninsured rates (such as possible Medicaid cuts or "upward pressure on the uninsured rate") could negatively impact prescription and service volumes, ultimately reducing McKesson's long-term revenue base in its core wholesale business.
In the rapidly changing healthcare delivery ecosystem (including growth of digital-first and direct-to-consumer models), McKesson faces execution risk with slow adaptation to technological transformation-any lag in automation, digitization, or strategic innovation versus competitors could erode operating margins and earnings sustainability in the long run.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $941.4 for McKesson based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1065.0, and the most bearish reporting a price target of just $812.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $499.3 billion, earnings will come to $6.1 billion, and it would be trading on a PE ratio of 20.7x, assuming you use a discount rate of 7.1%.
Given the current share price of $766.55, the analyst price target of $941.4 is 18.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on McKesson?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments